Cargando…

Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization

Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stab...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Rachel Yoon Kyung, Kwok, Philip Chi Lip, Khanal, Dipesh, Morales, Sandra, Kutter, Elizabeth, Li, Jian, Chan, Hak‐Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237144/
https://www.ncbi.nlm.nih.gov/pubmed/32440564
http://dx.doi.org/10.1002/btm2.10159
_version_ 1783536269051035648
author Chang, Rachel Yoon Kyung
Kwok, Philip Chi Lip
Khanal, Dipesh
Morales, Sandra
Kutter, Elizabeth
Li, Jian
Chan, Hak‐Kim
author_facet Chang, Rachel Yoon Kyung
Kwok, Philip Chi Lip
Khanal, Dipesh
Morales, Sandra
Kutter, Elizabeth
Li, Jian
Chan, Hak‐Kim
author_sort Chang, Rachel Yoon Kyung
collection PubMed
description Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stabilization mechanism is yet unknown. This paper reports the first study investigating the stabilization mechanism for phages in these powders. Proteins and other biologics are known to be preserved in dry state within a glassy sugar matrix at storage temperatures (T (s)) at least ~50°C below the glass transition temperature (T (g)). This is because at (T (g) − T (s)) >50°C, molecules are sufficiently immobilized with reduced reactivity. We hypothesized that this glass stabilization mechanism may also be applicable to phages comprising mostly of proteins. In this study, spray dried powders of Pseudomonas phage PEV20 containing lactose and leucine as excipients were stored at 5, 25 or 50°C and 15 or 33% relative humidity (RH), followed by assessment of bioactivity (PEV20 stability) and physical properties. PEV20 was stable with negligible titer loss after storage at 5°C/15% RH for 250 days, while storage at 33% RH caused increased titer losses of 1 log(10) and 3 log(10) at 5 and 25°C, respectively. The plasticizing effect of water at 33% RH lowered the T (g) by 30°C, thus narrowing the gap between T (s) and T (g) to 19–28°C, which was insufficient for glass stabilization. In contrast, the (T (g) − T (s)) values were higher (range, 46–65°C) under the drier condition of 15% RH, resulting in the improved stability which corroborated with the vitrification hypothesis. Furthermore, phage remained stable (≤1 log(10)) when the (T (g) − T (s)) value lay between 26–48°C, but became inactivated as the value fell below 20°C. In conclusion, this study demonstrated that phage can be sufficiently stabilized in spray dried powders by keeping the (T (g) − T (s)) value above 46°C, thus supporting the vitrification hypothesis that phages are stabilized by immobilization inside a rigid glassy sugar matrix. These findings provide a guide to better manufacture and storage practices of inhaled phage powder products using for translational medicines.
format Online
Article
Text
id pubmed-7237144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-72371442020-05-21 Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization Chang, Rachel Yoon Kyung Kwok, Philip Chi Lip Khanal, Dipesh Morales, Sandra Kutter, Elizabeth Li, Jian Chan, Hak‐Kim Bioeng Transl Med Research Reports Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stabilization mechanism is yet unknown. This paper reports the first study investigating the stabilization mechanism for phages in these powders. Proteins and other biologics are known to be preserved in dry state within a glassy sugar matrix at storage temperatures (T (s)) at least ~50°C below the glass transition temperature (T (g)). This is because at (T (g) − T (s)) >50°C, molecules are sufficiently immobilized with reduced reactivity. We hypothesized that this glass stabilization mechanism may also be applicable to phages comprising mostly of proteins. In this study, spray dried powders of Pseudomonas phage PEV20 containing lactose and leucine as excipients were stored at 5, 25 or 50°C and 15 or 33% relative humidity (RH), followed by assessment of bioactivity (PEV20 stability) and physical properties. PEV20 was stable with negligible titer loss after storage at 5°C/15% RH for 250 days, while storage at 33% RH caused increased titer losses of 1 log(10) and 3 log(10) at 5 and 25°C, respectively. The plasticizing effect of water at 33% RH lowered the T (g) by 30°C, thus narrowing the gap between T (s) and T (g) to 19–28°C, which was insufficient for glass stabilization. In contrast, the (T (g) − T (s)) values were higher (range, 46–65°C) under the drier condition of 15% RH, resulting in the improved stability which corroborated with the vitrification hypothesis. Furthermore, phage remained stable (≤1 log(10)) when the (T (g) − T (s)) value lay between 26–48°C, but became inactivated as the value fell below 20°C. In conclusion, this study demonstrated that phage can be sufficiently stabilized in spray dried powders by keeping the (T (g) − T (s)) value above 46°C, thus supporting the vitrification hypothesis that phages are stabilized by immobilization inside a rigid glassy sugar matrix. These findings provide a guide to better manufacture and storage practices of inhaled phage powder products using for translational medicines. John Wiley & Sons, Inc. 2020-04-14 /pmc/articles/PMC7237144/ /pubmed/32440564 http://dx.doi.org/10.1002/btm2.10159 Text en © 2020 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Chang, Rachel Yoon Kyung
Kwok, Philip Chi Lip
Khanal, Dipesh
Morales, Sandra
Kutter, Elizabeth
Li, Jian
Chan, Hak‐Kim
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title_full Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title_fullStr Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title_full_unstemmed Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title_short Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
title_sort inhalable bacteriophage powders: glass transition temperature and bioactivity stabilization
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237144/
https://www.ncbi.nlm.nih.gov/pubmed/32440564
http://dx.doi.org/10.1002/btm2.10159
work_keys_str_mv AT changrachelyoonkyung inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT kwokphilipchilip inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT khanaldipesh inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT moralessandra inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT kutterelizabeth inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT lijian inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization
AT chanhakkim inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization